Company news

Relay Therapeutics, Inc. (NASDAQ:RLAY) news

Relay Therapeutics, Inc. news releases on 6ix. Latest, Aug 6, 2026: Relay Therapeutics Reports Second Quarter 2026 Financial Results and Corporate Updates

Relay Therapeutics, Inc. (NASDAQ:RLAY) news

Press releases & updates

Relay Therapeutics Reports Second Quarter 2026 Financial Results and Corporate Updates

Relay Therapeutics to Announce Second Quarter 2026 Financial Results and Corporate Highlights on August 6, 2026

Relay Therapeutics Announces Initial Clinical Data Demonstrating That Zovegalisib Has Potential for Differentiated Safety and Efficacy in Patients with PIK3CA-Driven Vascular Anomalies

Relay Therapeutics Reports First Quarter 2026 Financial Results and Corporate Updates

Relay Therapeutics to Announce First Quarter 2026 Financial Results and Corporate Highlights on May 5, 2026

Relay Therapeutics Announces Clinical Data for Zovegalisib plus Atirmociclib Triplet Combination Supportive of Further Development in Frontline Metastatic Breast Cancer

Relay Therapeutics to Present Initial Clinical Data on Zovegalisib in Vascular Anomalies at the International Society for the Study of Vascular Anomalies World Congress 2026

Relay Therapeutics Announces Data from Zovegalisib + Fulvestrant at the Phase 3 Dose of 400mg BID Fed at ESMO Targeted Anticancer Therapies Congress 2026

Relay Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Outlines Anticipated 2026 Milestones

Relay Therapeutics to Participate in Two Upcoming Investor Conferences in March

Relay Therapeutics to Announce Fourth Quarter and Full Year 2025 Financial Results and Corporate Highlights on February 26, 2026

Relay Therapeutics to Participate in Guggenheim Emerging Outlook: Biotech Summit 2026

Relay Therapeutics Announces Zovegalisib Granted Breakthrough Therapy Designation by U.S. FDA for PIK3CA-mutant, HR+/HER2- Advanced Breast Cancer

Relay Therapeutics Announces Efficacy Subset Analysis of Zovegalisib (RLY-2608) + Fulvestrant in Breast Cancer Patients Pre-Treated with SERD or with ESR1 Mutations at SABCS 2025

Relay Therapeutics Reports Third Quarter 2025 Financial Results and Corporate Updates

Relay Therapeutics to Participate in Two Upcoming Investor Conferences in November

Relay Therapeutics to Announce Third Quarter 2025 Financial Results and Corporate Highlights on November 6, 2025

Relay Therapeutics to Participate in Two Upcoming Investor Conferences in September

Relay Therapeutics Reports Second Quarter 2025 Financial Results and Corporate Updates

Relay Therapeutics to Announce Second Quarter 2025 Financial Results and Corporate Highlights on August 7, 2025

Relay Therapeutics Appoints Claire Mazumdar, Ph.D., to Board of Directors

Relay Therapeutics Announces Updated Data for RLY-2608 + Fulvestrant Further Demonstrating Clinically Meaningful Progression Free Survival at ASCO 2025

Relay Therapeutics to Participate in Two Upcoming Investor Conferences in June

Relay Therapeutics to Participate in Two Upcoming Investor Conferences

Relay Therapeutics Reports First Quarter 2025 Financial Results and Corporate Updates

Relay Therapeutics to Announce First Quarter 2025 Financial Results and Corporate Highlights on May 5, 2025

Relay Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Updates

Relay Therapeutics to Announce Fourth Quarter and Full Year 2024 Financial Results and Corporate Highlights on February 26, 2025

Relay Therapeutics to Present at 43rd Annual J.P. Morgan Healthcare Conference

Relay Therapeutics Announces Updated Interim Data for RLY-2608 + Fulvestrant Demonstrating Continued Maturation of Clinically Meaningful Progression Free Survival

Relay Therapeutics to Present Updated Clinical Data on RLY-2608 in HR+/HER2- Breast Cancer at 2024 San Antonio Breast Cancer Symposium

Relay Therapeutics and Elevar Therapeutics Announce Exclusive Global Licensing Agreement for Lirafugratinib in FGFR2-Driven Cholangiocarcinoma and Other Solid Tumors

Relay Therapeutics to Participate in Upcoming Investor Conferences

Relay Therapeutics Reports Third Quarter 2024 Financial Results and Corporate Highlights

Relay Therapeutics to Announce Third Quarter 2024 Financial Results and Corporate Highlights on November 6, 2024

Relay Therapeutics Announces Pricing of Public Offering of Common Stock

Relay Therapeutics Announces Proposed Public Offering of Common Stock

Relay Therapeutics Announces Positive Interim Data for RLY-2608 Demonstrating Clinically Meaningful Progression Free Survival

Relay Therapeutics Announces Webcast to Report RLY-2608 Data on September 9, 2024

Relay Therapeutics Reports Second Quarter 2024 Financial Results and Corporate Highlights

Relay Therapeutics to Announce Second Quarter 2024 Financial Results and Corporate Highlights on August 6, 2024

Relay Therapeutics Discloses Three New Programs at New Program & Platform Event

Relay Therapeutics Announces Clinical Trial Collaboration with Pfizer to Evaluate Atirmociclib in Combination with RLY-2608

Relay Therapeutics to Host New Program and Platform Event on June 6, 2024

Relay Therapeutics Reports First Quarter 2024 Financial Results and Corporate Highlights

Relay Therapeutics to Announce First Quarter 2024 Financial Results and Corporate Highlights on May 2, 2024

Relay Therapeutics to Participate in Three Upcoming Investor Conferences

Relay Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Highlights

Relay Therapeutics to Announce Fourth Quarter and Full Year 2023 Financial Results and Corporate Highlights on February 22, 2024

Relay Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference